Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,356.00
Bid: 12,390.00
Ask: 12,394.00
Change: 28.00 (0.23%)
Spread: 4.00 (0.032%)
Open: 12,364.00
High: 12,454.00
Low: 12,322.00
Prev. Close: 12,328.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: Severn Trent deal sized up by CMA; Coca-Cola HBC buys

Mon, 19th Jun 2023 07:53

(Alliance News) - Stocks in London are called lower on Monday, ahead of more central bank decisions, while a meeting between US Secretary of State Antony Blinken and his Chinese counterpart put relations between the two nations back under the spotlight.

"With some US markets closed for the Juneteenth public holiday, today's European session is likely to be a quiet one, with a modestly negative open after US markets finished the end of a positive week, with their first daily decline in six days," CMC Markets analyst Michael Hewson commented.

The pound was on the front foot ahead of the Bank of England's interest rate decision on Thursday, with Threadneedle Street expected to enact a 25 basis point hike. There will be UK inflation data on Wednesday, ahead of the BoE decision.

There will also be interest rate decisions from the People's Bank of China on Tuesday, and the Swiss National Bank on Thursday.

Meanwhile, US Secretary of State Blinken met with his Chinese counterpart Qin Gang at the start of his two-day trip to Beijing, a visit aimed at rebuilding the cratering relationship between the world's two largest economies.

A series of meetings with high-ranking government representatives are planned before Blinken - the most senior US official to visit China in years - leaves on Monday. It remains unclear whether he will meet with Chinese leader Xi Jinping.

In early UK economic news, house prices fell marginally in June, according to Rightmove. In company news, AstraZeneca is said to be mulling a spin-off of its Chinese business. The UK competition watchdog said it is eyeing up Severn Trent's acquisition of a food waste anaerobic digestion plant operator.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: called down 34.0 points, 0.4%, at 7,608.72

----------

Hang Seng: down 1.1% at 19,815.13

Nikkei 225: closed down 0.9% at 33,400.47

S&P/ASX 200: closed up 0.6% at 7,294.90

----------

DJIA: closed down 108.94 points, 0.3%, at 34,299.12

S&P 500: closed down 0.4% at 4,409.59

Nasdaq Composite: closed down 0.7% at 13,689.57

----------

EUR: up at USD1.0941 (USD1.0926)

GBP: up at USD1.2825 (USD1.2819)

USD: up at JPY141.63 (JPY141.59)

GOLD: down at USD1,955.50 per ounce (USD1,960.83)

OIL (Brent): down at USD75.45 a barrel (USD75.62)

(changes since previous London equities close)

----------

ECONOMICS

----------

Monday's key economic events still to come:

US Juneteenth holiday. Financial markets closed.

11:00 BST Ireland goods exports and imports

----------

UK MPs vote Monday on a damning report that found ex-prime minister Boris Johnson deliberately lied to parliament about lockdown-breaking parties, in what the government hopes will be the final chapter in the damaging "Partygate" scandal. The parliamentary vote is being held on Johnson's 59th birthday as the wounded former leader ponders his next move, with allies predicting a future return to the electoral fray. It also comes at a time of mounting political problems for Rishi Sunak's Conservative government, as stubbornly high inflation and constantly rising interest rates inflict economic pain on voters.

----------

UK house prices suffered a marginal fall this month, the first June decline since 2017, according to a Rightmove tracker. Average new seller asking prices fell by just GBP82 in June to GBP372,812 from GBP372,894. Prices had risen 1.8% in May from April. Though fractional, June's outturn was the first monthly drop in asking prices this year. It was the first June fall in house prices since 2017. The outlook for house prices is less-than-stellar too, Rightmove predicts. The property portal expects asking prices to fall in most months for the rest of the year, in line with season patterns. Rightmove still predicts UK house prices to decline by 2% over the whole of 2023. Mortgage rates have increased recently, though Rightmove noted buyer demand has not been hurt. Demand over the last two weeks was 6% higher than in pre-pandemic 2019.

----------

BROKER RATING CHANGES

----------

Redburn raises Entain to 'buy' from 'neutral'

----------

HSBC raises Fevertree Drinks to 'buy' - price target 1,600 pence

----------

Deutsche Bank cuts Asos price target to 485 (725) pence - 'hold'

----------

COMPANIES - FTSE 100

----------

AstraZeneca has drafted plans to separate its China business amid geopolitical tensions, the Financial Times reported. The company is aiming to shield itself from simmering tensions between China, the world's second-largest economy, and the West. The FT, citing people familiar with the matter, reported that the Cambridge, England-based pharmaceutical company began discussing the idea with bankers "several months ago". It is among a growing number of multinational companies now considering that option, the FT added. A move may ultimately not take place, the FT sources said, though a Shanghai listing is also possible. The Chinese market is an attractive one for pharma firms, as the nation has an ageing population and as the government there speeds up the regulatory process for innovative medicines.

----------

The UK Competition & Markets Authority said it was looking at Severn Trent's acquisition of Andigestion to see whether it would lessen competition in the UK market. Back in February, the water utility had announced its green power unit's acquisition of Andigestion, which operates two food waste anaerobic digestion plants in southwest England. It said it expected the purchase to add another 45 gigawatt hours per year to its energy generation. "To assist it with this assessment, the CMA invites comments on the transaction from any interested party," the regulator said.

----------

Coca-Cola HBC announced it will acquire Brown-Forman Finland, which owns the Finlandia vodka brand, from Brown-Forman's Dutch subsidiary. It will pay USD220 million, and expects the acquisition to complete in the second half. It is subject to regulatory approvals. "Having been associated with the distribution of Finlandia for 17 years in several markets, we are excited by this unique and regionally relevant opportunity that will support the acceleration of our on-premise business across more of our markets," said Chief Executive Zoran Bogdanovic.

----------

COMPANIES - FTSE 250

----------

IT services provider Kainos said its CEO of 22 years, Brendan Mooney, will finish his term in the role by the end of September, with Digital Services Director Russell Sloan replacing him. Mooney will remain "actively engaged" with the business until next June, to ensure an orderly transition. "Brendan and Russell have worked closely as colleagues for many years and today formalises the final stage of our four-year succession process," said Chair Tom Burnet.

----------

RHI Magnesita received a partial cash offer for 30% of its shares from Ignite Luxembourg Holdings, a company indirectly managed by Rhone Holdings VI. Rhone is now offering GBP28.50 per share for 29.9% of the company. In late May, Rhone made a tilt for a 20% stake in the Vienna-based supplier of refractory products, also at GBP28.50 per share. At that time, it had said it reserved the right to increase the offer size to up to 29.9%. RHI Magnesita had said in May that its board was "considering its response to the partial offer and a further announcement will be made in due course".

----------

OTHER COMPANIES

----------

Life sciences firm Avacta Group denied media reports of plans for an imminent fundraising. "The company regularly considers potential funding opportunities, both non-dilutive and dilutive, to ensure its business operations remain well financed and the best interests of its stakeholders are maintained," it explained. Avacta said whilst it "[maintains] a dialogue" with shareholders and current investors, "no fundraising is imminent". It had cash of GBP27 million on the balance sheet at the end of May, and expects "strong news flow" in the coming months across the company.

----------

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
27 Jun 2024 13:00

German vaccine panel endorses Astra-Sanofi's RSV shot for infants

FRANKFURT, June 27 (Reuters) - Germany's influential vaccine advisory panel said on Thursday all infants in the country should receive AstraZeneca and Sanofi's antibody therapy to protect them against the common respiratory infection RSV.

Read more
26 Jun 2024 08:40

TOP NEWS: AstraZeneca's Tagrisso plus chemo gets approval in China

(Alliance News) - AstraZeneca PLC on Wednesday celebrated the approval of Tagrisso plus chemotherapy for a cancer form in China, a day after a similar approval in Japan.

Read more
25 Jun 2024 09:05

TOP NEWS: AstraZeneca details mixed findings from cancer drug trials

(Alliance News) - AstraZeneca PLC on Tuesday announced a mixed bag of results for two of its leading cancer drugs Imfinzi and Tagrisso.

Read more
25 Jun 2024 07:48

LONDON BRIEFING: Mixed bag for Astra drug; Landsec ups Bluewater stake

(Alliance News) - London's FTSE 100 is set to tread water on Tuesday, with a slump for US tech shares overnight keeping a lid on enthusiasm.

Read more
25 Jun 2024 07:17

AstraZeneca posts mixed results from recent Imfinzi trials

(Sharecast News) - AstraZeneca announced contrasting results from two phase three trials involving its immunotherapy drug 'Imfinzi', or durvalumab, on Tuesday.

Read more
24 Jun 2024 15:40

US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit

WASHINGTON, June 24 (Reuters) - The U.S. Supreme Court gave a boost on Monday to a challenge by 21 pharmaceutical and medical equipment companies led by AstraZeneca to a lawsuit accusing them of illegally helping to fund terrorism that killed or injured hundreds of American troops and civilians in Iraq.

Read more
24 Jun 2024 14:56

US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit

WASHINGTON, June 24 (Reuters) - The U.S. Supreme Court gave boost on Monday to a challenge by 21 pharmaceutical and medical equipment companies led by AstraZeneca to a lawsuit accusing them of illegally helping to fund terrorism that killed or injured hundreds of American troops and civilians in Iraq.

Read more
20 Jun 2024 10:56

TOP NEWS: AstraZeneca's Truqap gets OK from EU for breast cancer form

(Alliance News) - AstraZeneca PLC on Thursday said that the EU approved its prescription medicine Truqap, in combination with hormonal therapy Faslodex, for the treatment of a form of breast cancer.

Read more
18 Jun 2024 09:33

TOP NEWS: AstraZeneca disappointed by breast cancer drug trial results

(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.

Read more
18 Jun 2024 07:51

LONDON BRIEFING: Ashtead profit declines; Whitbread sales rise

(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with inflation data and central bank decisions the key plot points as the week progresses.

Read more
18 Jun 2024 07:17

AstraZeneca trial fails to treat 'challenging' breast cancer

(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with paclitaxel did not achieve its primary endpoints.

Read more
17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "important new option" for patients.

Read more
17 Jun 2024 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Bank of England.

Read more
17 Jun 2024 07:23

IN BRIEF: AstraZeneca gets positive cancer test results for Calquence

AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Reports promising test results for one of its cancer therapies. The Echo phase III trial shows that Calquence, when used in combination with bendamustine and rituximab, demonstrates a clinically meaningful improvement in progression-free survival in patients with untreated mantle cell lymphoma. Compared to standard-of-care chemoimmunotherapy, the combination with Calquence, whose generic name is acalabrutinib, shows a 27% reduced risk of disease progression or death. Mantle cell lymphoma is rare and typically aggressive form of non-Hodgkin lymphoma, Astra explains.

Read more
17 Jun 2024 07:15

AstraZeneca's Imfinzi gets US approval for endometrial cancer patients

(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.